Should I buy or sell Checkpoint Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CKPT shares. View CKPT analyst ratings or view top-rated stocks .

What is Checkpoint Therapeutics' stock price target for 2024?

5 Wall Street analysts have issued 12-month price objectives for Checkpoint Therapeutics' stock. Their CKPT share price targets range from $4.00 to $47.00. On average, they predict the company's stock price to reach $22.60 in the next twelve months. This suggests a possible upside of 1,312.5% from the stock's current price. View analysts price targets for CKPT or view top-rated stocks among Wall Street analysts .

How have CKPT shares performed in 2024?

Checkpoint Therapeutics' stock was trading at $2.29 at the beginning of the year. Since then, CKPT shares have decreased by 30.1% and is now trading at $1.60. View the best growth stocks for 2024 here .

When is Checkpoint Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CKPT earnings forecast .

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) posted its quarterly earnings results on Friday, March, 22nd. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $0.36. The company earned $0.01 million during the quarter, compared to analyst estimates of $0.09 million.

When did Checkpoint Therapeutics' stock split?

Checkpoint Therapeutics's stock reverse split before market open on Sunday, December 4th 2022. The 1-10 reverse split was announced on Sunday, December 4th 2022. The number of shares owned by shareholders was adjusted after the market closes on Sunday, December 4th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Checkpoint Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE) , Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , PTC Therapeutics (PTCT) , Dynavax Technologies (DVAX) , VBI Vaccines (VBIV) , SCYNEXIS (SCYX) , Aldeyra Therapeutics (ALDX) , Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL) .

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CKPT

Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free CKPT Stock Alerts

$1.60

-0.07 (-4.19%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.59
▼
$1.72
50-Day Range: $1.60
▼
$2.32
52-Week Range: $1.30
▼
$3.62

Volume: 469,359 shs
Average Volume: 336,677 shs
Market Capitalization: $57.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $22.60

Get Checkpoint Therapeutics alerts:

Checkpoint Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,312.5% Upside
$22.60 Price Target
Short Interest: Bearish
12.22% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.63
Upright™ Environmental Score
News Sentiment: 0.09
Based on 15 Articles This Week
Insider Trading: Selling Shares
$48,297 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.15 out of 5 stars

Medical Sector

318th out of 918 stocks

Pharmaceutical Preparations Industry

137th out of 430 stocks

3.5

Analyst's Opinion

Consensus Rating
Checkpoint Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Checkpoint Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
12.22% of the float of Checkpoint Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Checkpoint Therapeutics has a short interest ratio ("days to cover") of 6.9.
Change versus previous month
Short interest in Checkpoint Therapeutics has recently increased by 1.91%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Checkpoint Therapeutics does not currently pay a dividend.
Dividend Growth
Checkpoint Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Checkpoint Therapeutics has received a 62.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Checkpoint Therapeutics is -0.63.

2.3

News and Social Media Coverage

News Sentiment
Checkpoint Therapeutics has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 15 news articles for Checkpoint Therapeutics this week, compared to 2 articles on an average week.
Search Interest
14 people have searched for CKPT on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Checkpoint Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Checkpoint Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $48,297.00 in company stock.
Percentage Held by Insiders
Only 2.10% of the stock of Checkpoint Therapeutics is held by insiders.
Percentage Held by Institutions
Only 22.00% of the stock of Checkpoint Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Checkpoint Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Checkpoint Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Checkpoint Therapeutics Stock (NASDAQ:CKPT)

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is also developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

CKPT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CKPT Stock News Headlines

April 18, 2024 | businesswire.com

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (CKPT)

April 17, 2024 | markets.businessinsider.com

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 17, 2024 | tmcnet.com

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Checkpoint Therapeutics, Inc. (CKPT) Investors

April 16, 2024 | msn.com

PSP: Results from April 5 Sobriety Checkpoint

April 16, 2024 | stockhouse.com

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors Can Join the Class Action Lawsuit

April 16, 2024 | businesswire.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Checkpoint Therapeutics, Inc. (CKPT) Investors

April 15, 2024 | prnewswire.com

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 15, 2024 | businesswire.com

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Checkpoint Therapeutics, Inc. (CKPT) Investors

April 14, 2024 | markets.businessinsider.com

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

April 12, 2024 | prnewswire.com

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPT

April 12, 2024 | prnewswire.com

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPT

April 12, 2024 | markets.businessinsider.com

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

April 12, 2024 | businesswire.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

April 12, 2024 | businesswire.com

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

April 12, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPT

April 12, 2024 | markets.businessinsider.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

April 11, 2024 | businesswire.com

Checkpoint Therapeutics, Inc. Stockholder Alert: Robbins LLP Reminds Investors of the CKPT Class Action

April 10, 2024 | markets.businessinsider.com

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

April 10, 2024 | businesswire.com

The Law Offices of Frank R. Cruz Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

April 10, 2024 | businesswire.com

The Law Offices of Frank R. Cruz Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

April 9, 2024 | prnewswire.com

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

April 9, 2024 | businesswire.com

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CKPT

April 5, 2024 | prnewswire.com

Pomerantz Law Firm Announces the Filing of a Class Action Against Checkpoint Therapeutics, Inc. and Certain Officers - CKPT

March 29, 2024 | yahoo.com

Checkpoint Streaming: Watch & Stream Online via Netflix

March 24, 2024 | finance.yahoo.com

Checkpoint Therapeutics Full Year 2023 Earnings: Misses Expectations

See More Headlines

Receive CKPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/22/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CKPT
CUSIP: N/A
CIK: 1651407
Web: www.checkpointtx.com
Phone: (781) 652-4500
Fax: N/A
Employees: 23
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $22.60
High Stock Price Target: $47.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +1,312.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,850,000.00
Net Margins: -50,336.89%
Pretax Margin: -50,336.89%
Return on Equity: N/A
Return on Assets: -950.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.29
Quick Ratio: 0.29

Sales & Book Value

Annual Sales: $100,000.00
Price / Sales: 571.04
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.47) per share
Price / Book: -3.40

Miscellaneous

Outstanding Shares: 35,690,000
Free Float: 34,937,000
Market Cap: $57.10 million
Optionable: Optionable
Beta: 0.99

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. James F. Oliviero III (Age 48)
C.F.A., President, CEO & Director
Comp: $921.59k
Mr. William Garrett Gray (Age 37)
CFO, Corporate Secretary & Treasurer
Comp: $409.12k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CKPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Checkpoint Therapeutics stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CKPT shares.
View CKPT analyst ratings or view top-rated stocks.
What is Checkpoint Therapeutics' stock price target for 2024?: 5 Wall Street analysts have issued 12-month price objectives for Checkpoint Therapeutics' stock. Their CKPT share price targets range from $4.00 to $47.00. On average, they predict the company's stock price to reach $22.60 in the next twelve months. This suggests a possible upside of 1,312.5% from the stock's current price.
View analysts price targets for CKPT or view top-rated stocks among Wall Street analysts.
How have CKPT shares performed in 2024?: Checkpoint Therapeutics' stock was trading at $2.29 at the beginning of the year. Since then, CKPT shares have decreased by 30.1% and is now trading at $1.60.
View the best growth stocks for 2024 here.
When is Checkpoint Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CKPT earnings forecast.

How were Checkpoint Therapeutics' earnings last quarter?: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) posted its quarterly earnings results on Friday, March, 22nd. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $0.36. The company earned $0.01 million during the quarter, compared to analyst estimates of $0.09 million.
When did Checkpoint Therapeutics' stock split?: Checkpoint Therapeutics's stock reverse split before market open on Sunday, December 4th 2022. The 1-10 reverse split was announced on Sunday, December 4th 2022. The number of shares owned by shareholders was adjusted after the market closes on Sunday, December 4th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Checkpoint Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL).
How do I buy shares of Checkpoint Therapeutics?: Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CKPT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis

Checkpoint Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Checkpoint Therapeutics Stock (NASDAQ:CKPT)

CKPT Stock Price History

CKPT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CKPT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™